Oxycodone controlled release - Pain Therapeutics

Drug Profile

Oxycodone controlled release - Pain Therapeutics

Alternative Names: ORADUR®-oxycodone; Oxycodone extended release; PF-00345439; PTI-821; Remoxy; REMOXY® ER

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DURECT Corporation
  • Developer Pain Therapeutics
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 09 Aug 2017 Pain Therapeutics announces intention to resubmit NDA to the US FDA via the 505(b) pathway for Pain in the first quarter of 018 (91141)
  • 09 Aug 2017 Pain Therapeutics initiates an abuse potential phase II trial for intranasal route of abuse for oxycodone controlled release formulation
  • 09 Aug 2017 Pain Therapeutics completes enrolment in an phase II abuse potential trial for intranasal route of abuse for oxycodone controlled release formulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top